---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-043522"
form_type: "8-K"
ticker: null
cik: "0001621227"
company_name: "Adaptimmune Therapeutics PLC"
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:34:22.110220+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adaptimmune transfers listing to Nasdaq Capital Market; gets 180-day extension to regain $1.00 bid

## Summary
- Approval to transfer ADS listing from Nasdaq Global Select to Nasdaq Capital Market, effective May 2, 2025.
- ADSs non-compliant with $1.00 minimum bid price since Nov 1, 2024; 180-day extension now runs to Oct 27, 2025.
- To regain compliance, ADS bid price must be at least $1.00 for 10 consecutive business days within extended period.
- Failure to comply by Oct 27, 2025 may result in delisting from Nasdaq.
- Company monitors bid price and will evaluate actions to satisfy Listing Rule 5450(a)(1).

## SEC filing metadata
- accession: 0001104659-25-043522
- form_type: 8-K
- cik: 0001621227
- company_name: Adaptimmune Therapeutics PLC
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621227/000110465925043522/0001104659-25-043522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621227/000110465925043522/tm2513768d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-043522
- JSON: https://secwatch.observer/filing/0001104659-25-043522.json
- Plain text: https://secwatch.observer/filing/0001104659-25-043522.txt

## Key facts
- Listing & Compliance Notices
  Adaptimmune Therapeutics PLC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: May 1, 2025, Adaptimmune Therapeutics plc (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) approving the transfer of the listing of the Company’s American Depositary Shares (“ADSs”) from the Nasdaq Global Select Market to the Nasdaq Capital Market (the “Approval”). As previously reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission, on November 1, 2024, the Company received a notice from Nasdaq that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), because the minimum bid price of the Company’s ADSs has been be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465925043522/0001104659-25-043522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.